PGT-A in Brazil: embryo genetic testing in context.

Preimplantation genetic testing examines genetic material from an embryo before a possible transfer. PGT-A screens chromosome number (aneuploidy). It is one of several related tests: PGT-M targets a specific familial single-gene condition; PGT-SR addresses chromosome rearrangements. The indication and test design are agreed with the clinical and genetics teams.

More information is useful when it answers a meaningful question. Genetic testing belongs in a conversation about your medical history, your embryos and the decisions the results could inform. It is not a universal requirement for every IVF cycle.

Your physician and genetics team should explain whether testing is appropriate, which test is being discussed, and how the result could change your care.

Different tests address different questions. Chromosome-number screening is not the same as testing for a particular inherited condition in the family. Asking “which test, and why?” is more useful than assuming every IVF cycle includes PGT-A.

After retrieval, the laboratory assesses maturity and fertilization, then follows embryo development. If PGT is planned, biopsy and freezing generally precede a later transfer. Some patients need two trips—confirm whether your plan involves a return visit before locking non-flexible tickets.

A fresh transfer and a frozen transfer have different schedules. PGT results, endometrial preparation, your response and recovery may shift timing. Ask how biopsy, testing and results change the calendar for your stay in São Paulo or Porto Alegre.

Informed consent includes discussion of embryo biopsy, possible results, uncertainty and alternatives. A biopsy samples only some cells; mosaic, inconclusive and other complex results require careful interpretation.

Most international pathways begin with an online consultation, then assessment and preparation—some of which may take place near home when your physician agrees. Travel to São Paulo or Porto Alegre is timed around monitoring, retrieval and laboratory care. If embryos are biopsied and frozen, a later transfer visit may follow once results and endometrial preparation are ready.

A PGT result does not guarantee implantation, a healthy pregnancy or a live birth, and does not rule out every genetic or medical condition. PGT does not test for every disease or replace recommended prenatal screening and diagnostic discussions.

When you read outcome statistics, ask for live births rather than pregnancy alone; distinguish results per retrieval from results per transfer; and understand which denominators and age groups apply. This site does not publish clinic-specific live-birth marketing rates for PGT or non-PGT cycles.

CFM Resolution 2,320/2022 sets upper limits on embryo transfer according to recipient age, with a separate rule for euploid embryos after genetic diagnosis. Your physician explains how transfer decisions are framed for your plan.

SisEmbrio reports national activity figures for assisted reproduction in Brazil; those figures are activity reporting, not patient-specific live-birth marketing rates. Pair any clinic conversation about outcomes with clear denominators—and with an understanding of what PGT can and cannot change.

Leading Brazilian fertility laboratories—including the centers this program works with—describe technologies used in modern reproductive care: ICSI, time-lapse embryo culture, AI-supported assessment, embryo biopsy with PGT and vitrification. Availability of a technology does not mean it is suitable or necessary in every cycle.

ENNE Lab in São Paulo describes genetic testing among its published services. Laboratory care includes identity checks, documented handling, equipment monitoring, controlled storage and communication with the medical team within ANVISA’s reproductive-cell and embryo framework.

Brazil Fertility discloses treating clinics (ENNE and Nilo Frantz Medicina Reprodutiva) and does not claim separate laboratory accreditation as an organization beyond that disclosure. Ask your treating team which systems and checks apply to your cycle.

Vitrification supports freezing after biopsy when a later transfer is planned. Stored embryos must remain identifiable and traceable; consent, storage terms and decisions about future use form part of the treatment record.

Is PGT-A, PGT-M or PGT-SR being discussed—and what clinical question would the result answer? How will mosaic or inconclusive results be handled? How does biopsy timing affect freezing and a possible later transfer?

How are laboratory fees, testing fees and any return trip reflected in the treatment budget? Who interprets results with you—the physician, a genetics professional, or both? How do CFM transfer-limit rules interact with euploid embryo findings for your age and pathway?

These questions prepare you for a consult; they are not a substitute for individualized medical advice. Brazil Fertility helps you organize the conversation; clinical answers come from the treating team.

This site does not publish a standalone PGT-A fee schedule. Ask how laboratory fees, testing fees and any return trip are reflected in your treatment budget.

Our clinical group’s average IVF treatment cost in Brazil—around US$6,000–$8,000—considers corresponding categories including indicated genetic testing when part of that orientation average. It remains an average for orientation, not a package and not a personal quote. Individual use of services varies.

No individualized plan or final price can be established before consultations and necessary examinations.

If you are exploring IVF with possible embryo genetic testing in Brazil, start with an online consultation. Discuss whether any form of PGT answers a meaningful clinical question for you—and how it would affect travel and transfer timing.

Brazil Fertility coordinates English-speaking communication and practical support for international patients treated at ENNE or Nilo Frantz. Clinical and genetics decisions remain with your treating team.